Schubert & CO Arcus Biosciences, Inc. Transaction History

Schubert & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$15.96 - $23.15 $191 - $277	-12 Reduced 52.17%	11 $0
Q4 2022 Jan 31, 2023	BUY	$19.7 - $35.71 $98 - $178	5 Added 27.78%	23 $0
Q3 2022 Oct 21, 2022	BUY	$23.23 - $30.07 $46 - $60	2 Added 12.5%	18 $0
Q2 2022 Aug 01, 2022	BUY	$17.23 - $37.73 $241 - $528	14 Added 700.0%	16 $0
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $28 - $41	-1 Reduced 33.33%	2 $0
Q4 2021 Jan 28, 2022	BUY	$31.38 - $48.47 $94 - $145	3 New	3 $0

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.